Strong Revenue Growth
Mirum Pharmaceuticals reported total revenues of $128 million for the second quarter of 2025, representing a 64% growth over the same quarter last year.
Increased Full-Year Revenue Guidance
Given the growth observed, Mirum raised its full-year revenue guidance for 2025 to be between $490 million and $510 million, indicating close to 50% top line growth.
International Expansion Success
Livmarli saw durable growth internationally with $31 million in net product sales, driven by expanding reimbursement and strong performance in partner markets, including a successful launch in Japan by partner Takeda.
Pipeline Progress
Significant advancements in the pipeline, including the VISTAS Phase IIb study in primary sclerosing cholangitis (PSC) on track for completion, and the initiation of a Phase II study for MRM-3379 in Fragile X syndrome by the end of the year.
Positive Financial Performance
Mirum was cash flow positive for the quarter with cash, cash equivalents, and investments totaling $322 million, a $29 million increase from the end of last year.